|
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Number of employees : 171 people.
|
|
| 2019 | USD (in Million) | % | Pharmaceutical, Biotechnology and Other Drug Products | 22.11 | 100% |
|
|
| 2018 | 2019 | Delta | USD (in Million) | % | USD (in Million) | % | United States | 15.09 | 100% | 22.11 | 100% | +46.58% |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
134,721,125 |
133,445,844 |
99.1% |
522,957 |
0.4% |
99.1% |
|
|
Name | Equities | % | Heights Capital Management, Inc. | 4,918,972 |
5.25% | Anson Funds Management LP | 3,013,054 |
3.22% | The Vanguard Group, Inc. | 2,045,857 |
2.18% | 683 Capital Management LLC | 1,938,825 |
2.07% | Sio Capital Management LLC | 1,935,961 |
2.07% | First Manhattan Co. | 1,391,733 |
1.49% | BlackRock Fund Advisors | 1,325,349 |
1.42% | Deka Investment GmbH | 1,200,000 |
1.28% | Maven Investment Partners US Ltd. | 1,000,000 |
1.07% | Geode Capital Management LLC | 558,447 |
0.60% |
|
Company contact information |
|
|
|
|
Sector Other Pharmaceuticals
|